Please note: This page is deliberately detailed. It is based on a broad review of Roche’s public governance, product and pipeline material. Readers may find it easier to explore by asking a specific question with the help of their AI assistant.
TLDR: Roche is organised around two customer-facing businesses: diagnostics and medicines. Diagnostics supplies the testing infrastructure used in laboratories, pathology, sequencing, molecular testing, point-of-care care and digital workflows. Pharma develops and commercialises medicines across oncology, haematology, neuroscience, immunology, ophthalmology, infectious disease and cardiovascular, renal and metabolic disease. Its development system is layered: pRED and gRED generate early science, Global Product Development advances selected assets through clinical development and approval, and marketed-product programmes extend approved medicines into new indications, combinations and formulations. Roche’s structure is therefore best read as a regulated healthcare operating system: governance controls the company, divisions commercialise products, research engines create assets, and partners add specialist capability.
We often profile companies from foundation to maturity to understand how scientific infrastructure becomes durable. Roche is included because its scale, management structure and collaboration model show how diagnostics, medicines and research are organised in a mature healthcare company.
Here, we map Roche’s customer-facing products, development programmes, governance and organisational units.
Roche in one view
| Area | Role in Roche | Main examples |
|---|---|---|
| Diagnostics | Testing systems, lab platforms, assays, sequencing and digital tools | cobas, VENTANA, navify, Elecsys, AXELIOS |
| Pharma | Medicines across major therapeutic areas | Tecentriq, Ocrevus, Vabysmo, Hemlibra, Actemra |
| pRED | Roche Pharma Research and Early Development | Brainshuttle, ASO, PanRAS, MAGL inhibitor |
| gRED | Genentech Research and Early Development | KRAS, CAR-T, bispecifics, cancer vaccines |
| Global Product Development | Later-stage clinical development and regulatory execution | Phase 2, Phase 3, filings and approvals |
| Chugai | Japanese affiliate and innovation partner | Alecensa, Hemlibra, Enspryng, PiaSky |
| External partners | Specialist technologies and co-development | BioNTech, Ionis, Alnylam, Carmot, Telavant, Sarepta |
How Roche is organised
Roche Pharmaceuticals is responsible for medicines, therapeutic development and marketed-product lifecycle expansion. Roche Diagnostics is responsible for laboratory systems, molecular testing, pathology, point-of-care diagnostics, sequencing and digital diagnostic infrastructure.
Roche’s pharma research and development structure has several layers. pRED is Roche Pharma Research and Early Development. gRED is Genentech Research and Early Development. Global Product Development takes selected assets through later-stage development, registration and approval. Marketed product development extends approved medicines into new indications, combinations and formulations.
Chugai sits within the wider Roche system as a Japanese affiliate and innovation partner. Roche also uses external partnerships to access specific technologies, modalities and disease-area expertise.
Governance and control
Roche’s governance structure is built around the Annual General Meeting, the Board of Directors, Board committees, the Executive Committee and the Articles of Incorporation of Roche Holding Ltd. The Annual General Meeting elects Board members each year, with each nominee voted on separately. The Board is the highest authority for management and supervision of the company.
Former Board member CVs are archived here: https://www.roche.com/about/governance/archiv-former-cvs
Board of Directors
Last update: 11 March 2026.
| Name | Year of birth | Position | Committees | Term ends | First election |
|---|---|---|---|---|---|
| Dr Severin Schwan | 1967 | Chairman | D*, E | 2027 | 2023 as Chairman, 2013 as Board member |
| André Hoffmann | 1958 | Vice-Chairman, representative of shareholder group with pooled voting rights | A*, D, E, G | 2027 | 1996 |
| Dr Jörg Duschmalé | 1984 | Representative of shareholder group with pooled voting rights | B, C*, E, G | 2027 | 2020 |
| Dr Patrick Frost | 1968 | Board member | B*, E, G | 2027 | 2020 |
| Anita Hauser | 1969 | Board member | C, D, E, G | 2027 | 2017 |
| Prof Dr Akiko Iwasaki | 1970 | Board member | A, E, G | 2027 | 2023 |
| Prof Dr Richard P. Lifton | 1953 | Board member | C, E, G | 2027 | 2015 |
| Dr Jemilah Mahmood | 1959 | Board member | A, E, G | 2027 | 2022 |
| Lubomira Rochet | 1977 | Board member | B, E, G | 2027 | 2026 |
| Dr Mark Schneider | 1965 | Board member | B, E, G | 2027 | 2023 |
| Code | Meaning |
|---|---|
| A | Corporate Governance and Sustainability Committee |
| B | Audit Committee |
| C | Remuneration Committee |
| D | Chairman’s Committee / Nomination Committee |
| E | Non-executive member |
| F | Executive director, currently no member |
| G | Independent director |
| * | Committee chair |
Per-Olof Attinger serves as Secretary to the Board of Directors.
Board committees
| Committee | Main role |
|---|---|
| Chairman’s / Nomination Committee | Board resolutions, implementation, succession and candidate evaluation |
| Audit Committee | Financial reporting, audit, internal controls, tax and risk management |
| Corporate Governance and Sustainability Committee | Governance, non-financial reporting, compliance, sustainability, safety and environment |
| Remuneration Committee | Board and Executive Committee remuneration, bonuses and equity plans |
Roche states that its target is for more than 50% of the Board to be independent. Roche also states that all Board seats are held by independent directors except Dr Severin Schwan, due to his former executive role as CEO until 14 March 2023. A third-party Board assessment took place in 2025.
Executive Committee
| Name | Year of birth | Position | Member since |
|---|---|---|---|
| Dr Thomas Schinecker | 1975 | Chief Executive Officer, Roche Group | 2019 |
| Teresa Graham | 1973 | CEO Roche Pharmaceuticals | 2023 |
| Matt Sause | 1977 | CEO Roche Diagnostics | 2023 |
| Dr Alan Hippe | 1967 | Chief Financial Officer | 2011 |
| Cristina A. Wilbur | 1967 | Chief People Officer | 2016 |
Enlarged Corporate Executive Committee
| Name | Year of birth | Position | Member since |
|---|---|---|---|
| Claudia Böckstiegel | 1964 | General Counsel | 2020 |
| Prof Dr Mark Dawson | 1974 | Head of Roche Pharma Research and Early Development, pRED | 2026 |
| Dr Levi Garraway | 1968 | Head of Global Product Development and Chief Medical Officer | 2023 |
| Silke Hörnstein | 1975 | Head of Corporate Strategy and Sustainability | 2023 |
| Wafaa Mamilli | 1967 | Chief Digital and Technology Officer | 2025 |
| Dr Aviv Regev | 1971 | Head of Genentech Research and Early Development, gRED | 2020 |
| Dr Nina Schwab-Hautzinger | 1975 | Head of Group Communications | 2026 |
| Boris L. Zaïtra | 1972 | Head of Corporate Business Development | 2024 |
Silke Hörnstein also serves as Secretary to the Corporate Executive Committee.
Articles of Incorporation
Roche Holding Ltd is a Swiss joint-stock company headquartered in Basel. Its purpose is to hold shares in companies that manufacture and sell pharmaceutical and chemical products. Roche’s share capital is CHF 106,691,000, divided into 106,691,000 fully paid bearer shares with a nominal value of CHF 1 each.
Roche also has 702,562,700 bearer non-voting equity securities, known as Genussscheine. These are not part of the share capital and do not confer voting rights, but they confer rights to participate in available earnings and liquidation proceeds under the Articles.
The statutory bodies are the General Meeting, the Board of Directors and the Auditors. The Ordinary General Meeting must be held each year by 30 June. It approves key matters including the Articles, financial statements, dividends, Board and Executive Committee remuneration, elections and liquidation decisions.
Diagnostics
Roche Diagnostics supplies testing infrastructure. Its work spans core laboratory testing, molecular diagnostics, blood screening, pathology, point-of-care testing, sequencing and digital solutions.
Diagnostics health topics
| Topic |
|---|
| Cardiometabolic diseases |
| Infectious diseases |
| Neurology |
| Oncology |
| Women’s health |
Diagnostics solution areas
| Area | Role |
|---|---|
| Blood screening | Testing for donor and transfusion safety |
| Core lab | High-volume clinical chemistry and immunoassay testing |
| Digital solutions | Software, data, analytics and workflow tools |
| Molecular lab | PCR and molecular diagnostic testing |
| Pathology lab | Tissue diagnostics, staining and digital pathology |
| Point of care | Testing closer to the patient |
| Sequencing | NGS workflows, library preparation and sequencing systems |
Diagnostics product brands
| Brand | What it is for |
|---|---|
| cobas® | Connected in vitro diagnostics platform |
| KAPA | NGS sample preparation workflows |
| TIB Molbiol | Flexible PCR assay portfolio |
| VENTANA® | Pathology and tissue diagnostics products |
| Harmony® | Non-invasive prenatal screening test |
| CoaguChek® | Point-of-care coagulation monitoring |
| MagNA Pure | Automated nucleic acid purification |
| navify® | Digital healthcare and laboratory solutions |
| LightCycler® | Real-time quantitative PCR system |
| CustomBiotech | Biopharma and diagnostics components |
Diagnostics digital solutions pipeline
| Year | Area | Product | Purpose | Market |
|---|---|---|---|---|
| 2021 | Core lab | Elecsys® GAAD Algorithm | Early HCC detection in chronic liver disease | CE |
| 2021 | Diabetes care | Accu-Chek SugarView | Smartphone-based glucose testing | OUS |
| 2021 | Remote monitoring | RDCP module | Remote diabetes patient interaction | WW |
| 2021 | Insights | NAVIFY Pass 1.0 | SARS-CoV-2 rapid antigen result sharing | US, CE |
| 2021 | Oncology | NAVIFY Oncology 1.0 | Oncology decision support | WW |
| 2022 | Diabetes care | mySugar Pump V2.0 | Basal-rate data and expanded smartphone compatibility | OUS |
| 2022 | Diabetes care | Payer Dashboard | Diabetes population dashboard for administrators and payers | OUS |
| 2022 | Lab insights | Lab Insights Platform | Cross-discipline lab data integration | CE |
| 2022 | Lab insights | cobas® infinity edge suite | Digital support for decentralised testing and data | CE |
| 2022 | Cervical cancer screening | Cervical screening app and workflow | Screening programme management | CE |
| 2022 | Chronic kidney disease | Chronic Kidney Disease InSight | Patient management app and dashboard | CE |
| 2023 | Lab insights | navify Sample Tracking | Sample traceability beyond the lab | WW |
| 2023 | Lab insights | navify Marketplace | Marketplace for Roche and third-party applications | WW |
| 2023 | Lab insights | cobas infinity lab 3.05 | Lab middleware for cloud-based quality control and maintenance | WW |
| 2023 | Pathology lab | Menu for navify Algorithm Suite | Certified oncology algorithms including colon and liver cancer applications | WW |
| 2023 | Pathology lab | navify Algorithm Suite | Library of certified IVD clinical algorithms | WW |
| 2023 | Pathology lab | RUO Digital Pathology Algorithm: PD-L1 SP142 | Research-use digital pathology algorithm for PD-L1 breast sample scoring | WW |
| 2024 | Diagnostics insights | navify Analytics family | Laboratory operational analytics across core, pathology, molecular and point of care | WW |
| 2025 | Healthcare insights | Kidney Klinrisk algorithm | End-stage kidney disease risk assessment | CE |
| 2025 | Healthcare insights | Chest Pain Triage algorithm | Emergency chest pain triage | CE |
| 2025 | Pathology lab | navify® Digital Pathology 3.0 | Digital pathology image management update | CE |
Diagnostics instruments and devices pipeline
| Year | Area | Product | Purpose | Market |
|---|---|---|---|---|
| 2021 | Core lab | cobas® pro integrated solutions | High-throughput serum work area system | CE |
| 2021 | Core lab | cobas® pure integrated solutions | Low-to-medium volume serum work area system | CE |
| 2021 | Diabetes care | Accu-Chek Instant Forward | Performance and user-experience update for Instant meter | WW |
| 2021 | Molecular lab | AVENIO Edge System | Automated sequencing library preparation and target enrichment | WW |
| 2021 | Molecular lab | cobas® 5800 | Low-throughput PCR system | CE |
| 2021 | Point of care | cobas® pulse | Successor to Accu-Chek® Inform II | CE |
| 2022 | Core lab | cobas® pure integrated solutions | Serum work area analyser for low-to-medium sized labs | US |
| 2022 | Molecular lab | Digital LightCycler | Digital PCR platform for LDT and IVD laboratories | WW |
| 2022 | Molecular lab | cobas® 5800 | PCR system for lower-volume labs | US |
| 2022 | Pathology lab | DP600 | High-capacity slide scanner | WW |
| 2022 | Pathology lab | BenchMark ULTRA PLUS | Automated IHC and ISH staining platform | US, CE |
| 2022 | Point of care | cobas® pulse | Glucose meter with digital clinical decision-support platform | US |
| 2023 | Core lab | cobas pure integrated solutions | Low-to-mid volume clinical chemistry and immunochemistry system | China |
| 2023 | Core lab | cobas pro integrated solutions | Mid-to-high volume clinical chemistry and immunochemistry system | China |
| 2023 | Core lab | CCM Vertical | Overhead sample transport system | WW |
| 2023 | Molecular lab | LightCycler Pro | Real-time PCR instrument with IVD and research modes | US, CE |
| 2023 | Point of care | cobas pulse | Glucose meter with digital decision-support platform | US |
| 2024 | Core lab | cobas ISE neo | High-throughput ISE testing for cobas pro | CE |
| 2024 | Core lab | cobas c703 | High-throughput clinical chemistry testing for cobas pro | CE |
| 2024 | Core lab | i601 mass spectrometry system | Automated clinical mass spectrometry system | CE |
| 2024 | Molecular lab | cobas 6800/8800 v2.0 | Upgraded high-throughput PCR system | CE |
| 2024 | Near patient care | Accu-Chek SmartGuide | Continuous glucose monitoring | CE |
| 2024 | Pathology lab | Primary Diagnosis Claim on DP600 US | FDA 510k primary diagnosis clearance for DP600 scanner | US |
Diagnostics tests and assays pipeline
| Year | Area | Product | Purpose | Market |
|---|---|---|---|---|
| 2021 | Core lab | Elecsys® TnT-hs claim extensions | Cardiovascular intended-use extensions | CE |
| 2021 | Core lab | Elecsys® NT-proBNP IU | Cardiovascular intended-use extensions | CE |
| 2021 | Core lab | Elecsys® SARS-CoV-2 Antigen | Automated SARS-CoV-2 antigen assay | US |
| 2021 | Molecular lab | KAPA HyperPETE kit | Targeted sequencing kit using primer extension | WW |
| 2021 | Molecular lab | AVENIO FoundationOne kit, RUO | Decentralised FoundationOne research-use kit | WW |
| 2022 | Core lab | Elecsys pTau/AB42 ratio Gen2, CSF | Alzheimer’s amyloid disease testing | US |
| 2022 | Core lab | cobas® HCV Duo | Combined HCV antigen and antibody assay | CE |
| 2022 | Molecular lab | cobas® 5800 Menu Expansion | SARS-CoV-2, CT/NG and CMV assays | US, CE |
| 2022 | Molecular lab | cobas® SARS-CoV-2 DUO | Automated RT-PCR assay for cobas® 6800/8800 | US, OUS |
| 2022 | Pathology lab | HPV Self Sampling | Home sample collection for cervical cancer testing | CE |
| 2022 | Pathology lab | PRAME | IHC assay for differential diagnosis of melanocytic lesions | US, CE |
| 2022 | Pathology lab | HER2 Low Breast | HER2-low breast cancer assay | US |
| 2023 | Core lab | RUO Amyloid Plasma Assays, pTau181 and ApoE4 | Alzheimer’s research immunoassays | US |
| 2023 | Core lab | IL-6 Neonatal sepsis claim extension | Neonatal sepsis diagnostic claim extension | CE |
| 2023 | Core lab | HBeAg Quant | Hepatitis B diagnosis, monitoring and treatment-response assay | CE |
| 2023 | Core lab | Anti-HEV IgG and Anti-HEV IgM | Hepatitis E infection and seroprevalence assays | CE |
| 2023 | Pathology lab | IDH1 R132H, IDH Glioma | IHC solution for glioma diagnosis | US |
| 2024 | Core lab | cobas pro serology solution, blood screening | Roche Blood Safety Solution for US donor screening | US |
| 2024 | Molecular lab | cobas Malaria, blood screening | PCR test detecting five human Plasmodium species | CE, US |
| 2024 | Molecular lab | cobas Respiratory flex | Flexible respiratory PCR testing using TAGS® multiplex technology | CE, US |
| 2024 | Near patient care | cobas Liat Respiratory Panel | SARS-CoV-2, influenza A/B and RSV testing | US, EUA |
| 2024 | Pathology lab | VENTANA Kappa Lambda Dual ISH mRNA Probe Cocktail | Aid in diagnosis of B-cell lymphomas and plasma cell neoplasms | CE, US |
| 2025 | Core lab | Elecsys® Dengue Ag | Early dengue infection testing | CE |
| 2025 | Core lab | Elecsys® Pepsinogen 1 and 2 | Advanced atrophic gastritis and gastric cancer risk testing | China |
| 2025 | Core lab | cobas® i601 Mass Spectrometry wave 1 ipacks | Broad assay menu for cobas i601 mass spectrometry system | CE |
| 2025 | Core lab | Elecsys® Pro-C3 ADAPT | Liver fibrosis assessment in MASLD/MASH | CE |
| 2025 | Core lab | Elecsys® high-sensitivity Troponin-T Generation 6 | Acute myocardial infarction diagnosis | CE |
| 2025 | Core lab | Elecsys® pTau181 | Blood-based Alzheimer’s biomarker | CE |
| 2025 | Molecular lab | cobas® BV/CV | Bacterial vaginosis and Candida vaginitis molecular testing | CE |
| 2025 | Near patient care | cobas® liat CT/NG | Rapid chlamydia and gonorrhoea testing | US |
| 2026 | Core lab | Elecsys® ApoE4p | Blood-based Alzheimer’s genetic risk biomarker | CE |
| 2026 | Core lab | Elecsys® NfL | Blood-based multiple sclerosis disease activity biomarker | CE |
| 2026 | Molecular lab | cobas® MPX-E | HIV, HCV, HBV and HEV donor-screening PCR assay | CE |
Diagnostics key launches 2026
| Area | Product | Purpose | Market or status |
|---|---|---|---|
| Sequencing | AXELIOS Sequencing Solution | High-throughput sequencing platform for ultra-rapid, scalable and flexible sequencing | 2026 launch |
| Core lab | Elecsys® pTau 217 | Blood-based Alzheimer’s biomarker | 2026 launch |
| Core lab | Elecsys® NfL | Blood-based neurological disease activity biomarker, including multiple sclerosis | 2026 launch |
| Core lab | Elecsys® ApoE4p | Blood-based Alzheimer’s genetic risk biomarker | 2026 launch |
| Core lab | Elecsys® IGRA TB | Latent tuberculosis detection | 2026 launch |
| Molecular lab | cobas® MPX-E | Donor screening across HIV, HCV, HBV and HEV | CE |
| Molecular lab | cobas® HDV | Hepatitis D diagnosis and monitoring | 2026 launch |
| Molecular lab | ePlex gastrointestinal panel | Broad gastrointestinal pathogen detection | 2026 launch |
| Near patient care | cobas® liat lesion panel EUA | Rapid differential diagnosis of cutaneous and mucocutaneous lesions | EUA |
| Pathology | VENTANA® BAP1 | Differentiation of mesothelioma from benign mesothelial proliferation | 2026 launch |
| Digital health | LungFlag algorithm | Machine-learning tool to identify patients at high risk of lung cancer | 2026 launch |
Pharma
Roche Pharmaceuticals develops and commercialises medicines. Its visible portfolio spans oncology, haematology, neurological disease, ophthalmology, immunology, infectious disease, respiratory disease, transplantation, dermatology and anaemia.
Pharma focus areas
| Area |
|---|
| Anaemia |
| Blood cancers |
| Solid tumours |
| Dermatology |
| Haematology |
| Infectious diseases |
| Inflammatory and autoimmune diseases |
| Neurological disorders |
| Ophthalmology |
| Respiratory disorders |
| Transplantation |
Marketed pharma products
| Product | Main use |
|---|---|
| Actemra/RoActemra | Inflammatory autoimmune treatment |
| Alecensa | Lung cancer treatment |
| Avastin | Solid tumour cancer treatment |
| CellCept | Transplant rejection prevention |
| Columvi | Blood cancer treatment |
| Cotellic | Melanoma cancer treatment |
| Enspryng | Neurological autoimmune disorder treatment |
| Erivedge | Skin cancer treatment |
| Esbriet | Lung fibrosis treatment |
| Evrysdi | Spinal muscular atrophy treatment |
| Fuzeon | HIV treatment |
| Gazyva/Gazyvaro | Blood cancer treatment |
| Hemlibra | Haemophilia treatment |
| Herceptin | HER2-positive cancer treatment |
| Herceptin SC / Herceptin Hylecta | Injectable HER2-positive cancer treatment |
| Itovebi | Breast cancer treatment |
| Kadcyla | HER2-positive breast cancer treatment |
| Lunsumio | Blood cancer treatment |
| MabThera / Rituxan | Blood cancer and autoimmune treatment |
| MabThera SC / Rituxan Hycela | Injectable rituximab treatment |
| Madopar | Parkinson’s disease treatment |
| Mircera | Anaemia treatment |
| NeoRecormon | Anaemia treatment |
| Ocrevus | Multiple sclerosis treatment |
| Perjeta | HER2-positive breast cancer treatment |
| Phesgo | Injectable HER2-positive breast cancer treatment |
| PiaSky | Blood disorder treatment |
| Polivy | Blood cancer treatment |
| Pulmozyme | Cystic fibrosis treatment |
| Roaccutane/Accutane | Severe acne treatment |
| Rocephin | Antibiotic treatment |
| Rozlytrek | Targeted cancer treatment |
| Susvimo | Eye disease treatment |
| Tamiflu | Influenza treatment |
| Tecentriq | Cancer immunotherapy |
| Vabysmo | Eye disease treatment |
| Xofluza | Influenza treatment |
| Zelboraf | Melanoma cancer treatment |
Pharma development architecture
Roche’s pharma development pipeline has four main layers. Marketed product development extends approved medicines into new indications, combinations and formulations. Roche Pharma global development moves later-stage assets through Phase 2, Phase 3, filing and approval. pRED develops Roche-originated early research and clinical assets. gRED develops Genentech-originated early research and clinical assets.
The source pipeline information for this page was reviewed in May 2026. The Roche product development pipeline referenced in the notes was last updated on 23 April 2026.
Pharma development areas
| Area |
|---|
| Oncology and haematology |
| Neuroscience |
| Ophthalmology |
| Immunology |
| Cardiovascular, renal and metabolism |
| Infectious diseases and acute care |
Marketed products development programmes
| Product or asset | Area | Development layer | Status or focus | Partner |
|---|---|---|---|---|
| Alecensa / alectinib | Oncology and haematology | Marketed product development | ALK-positive lung cancer, including adjuvant ALK-positive NSCLC | Chugai |
| Itovebi / inavolisib | Oncology and haematology | Marketed product development | PI3K-mutant breast cancer and prostate cancer combinations | Roche |
| Kadcyla / trastuzumab emtansine | Oncology and haematology | Marketed product development | HER2-positive breast cancer, including combination with Tecentriq | ImmunoGen |
| Tecentriq / atezolizumab | Oncology and haematology | Marketed product development | Cancer immunotherapy, bladder and lung cancer, subcutaneous formulation | Halozyme, Jazz Pharma |
| Columvi / glofitamab | Oncology and haematology | Marketed product development | B-cell blood cancers, DLBCL and mantle cell lymphoma | Roche |
| Lunsumio / mosunetuzumab | Oncology, haematology and immunology | Marketed product development | Follicular lymphoma, DLBCL, haematologic tumours and SLE | Biogen Idec |
| Polivy / polatuzumab vedotin | Oncology and haematology | Marketed product development | Diffuse large B-cell lymphoma | Seagen |
| Hemlibra / emicizumab | Haematology | Marketed product development | Haemophilia and type 3 VWD | Chugai |
| PiaSky / crovalimab | Haematology and complement disease | Marketed product development | PNH, aHUS and complement-mediated disease | Chugai |
| Elevidys / delandistrogene moxeparvovec | Neuroscience | Marketed product development | Duchenne muscular dystrophy gene therapy | Sarepta |
| Enspryng / satralizumab | Neuroscience and ophthalmology | Marketed product development | Autoimmune encephalitis, MOG-AD and thyroid eye disease | Chugai |
| Evrysdi / risdiplam | Neuroscience | Marketed product development | Spinal muscular atrophy | PTC Therapeutics, SMA Foundation |
| Gazyva/Gazyvaro / obinutuzumab | Immunology and haematology | Marketed product development | SLE, lupus nephritis, membranous nephropathy and paediatric nephrotic syndrome | Biogen Idec |
| Susvimo / ranibizumab port delivery | Ophthalmology | Marketed product development | AMD, DME and diabetic retinopathy | ForSight VISION4 |
| Vabysmo / faricimab | Ophthalmology | Marketed product development | AMD, DME, retinal vein occlusion and myopic CNV | Roche |
| Xofluza / baloxavir marboxil | Infectious disease | Marketed product development | Influenza in paediatric patients | Shionogi |
| Actemra/RoActemra / tocilizumab | Immunology | Marketed product development | COVID-19 pneumonia and inflammatory disease | Chugai |
| Ocrevus SC / ocrelizumab | Neuroscience | Marketed product development | Relapsing and primary progressive multiple sclerosis | Halozyme, Biogen Idec |
Roche Pharma global development programmes
| Product or asset | Area | Development layer | Status or phase | Partner |
|---|---|---|---|---|
| divarasib, KRAS G12C | Oncology and haematology | Global development | Phase 1 and Phase 3, solid tumours and NSCLC | Roche |
| giredestrant | Oncology and haematology | Global development | Filed, Phase 3 and Phase 2, ER-positive breast and endometrial cancer | Roche |
| NXT007 / anti-FIXa/FX | Haematology | Global development | Phase 2, haemophilia A | Chugai |
| dirloctogene samoparvovec / SPK-8011QQ | Haematology | Global development | Phase 2, haemophilia A gene therapy | Spark Therapeutics |
| fenebrutinib | Neuroscience | Global development | Phase 3, relapsing and primary progressive MS | Roche |
| prasinezumab | Neuroscience | Global development | Phase 3, Parkinson’s disease | Prothena |
| tominersen | Neuroscience | Global development | Phase 2, Huntington’s disease | Ionis |
| trontinemab | Neuroscience | Global development | Phase 3, Alzheimer’s disease | Roche |
| sefaxersen / ASO factor B | Immunology and renal disease | Global development | Phase 3, IgA nephropathy | Ionis |
| afimkibart / anti-TL1A | Immunology | Global development | Phase 2 and Phase 3, ulcerative colitis, Crohn’s, RA, atopic dermatitis and MASH | Telavant |
| vamikibart | Ophthalmology | Global development | Phase 3, uveitic macular oedema and DME | Roche |
| zilebesiran | CVRM | Global development | Phase 3, hypertension | Alnylam Pharmaceuticals |
| enicepatide / CT-388 | CVRM | Global development | Phase 3, obesity and type 2 diabetes | Carmot Therapeutics |
| GLP-1 receptor agonist / CT-996 | CVRM | Global development | Phase 2, obesity and type 2 diabetes | Carmot Therapeutics |
| acmopatide / CT-868 | CVRM | Global development | Phase 2, type 1 diabetes and weight control | Carmot Therapeutics |
| emugrobart / GYM 329 | CVRM | Global development | Phase 2, obesity and muscle preservation | Chugai |
| pegozafermin | CVRM | Global development | Phase 3, MASH with fibrosis | 89bio |
| petrelintide | CVRM | Global development | Phase 2, obesity and type 2 diabetes | Zealand |
| astegolimab / anti-ST2 | Immunology and respiratory disease | Global development | Phase 3, COPD | Amgen |
| p40 x TL1A bispecific | Immunology | Global development | Phase 2, ulcerative colitis | Pfizer |
Roche Pharma research and early development, pRED
| Product or asset | Area | Development layer | Status or focus | Partner |
|---|---|---|---|---|
| mosperafenib / BRAF inhibitor | Oncology and haematology | pRED | Phase 1, BRAF V600 solid tumours | Roche |
| CEA12Pb PRIT | Oncology and haematology | pRED | Phase 1, metastatic colorectal cancer | Roche |
| PanRAS inhibitor | Oncology and haematology | pRED | Phase 1, solid tumours | Roche |
| Brainshuttle™ CD20 | Neuroscience | pRED | Phase 1, multiple sclerosis | Roche |
| nivegacetor / gamma-secretase modulator | Neuroscience | pRED | Phase 2, Alzheimer’s disease | Roche |
| MAGL inhibitor | Neuroscience | pRED | Phase 2, multiple sclerosis | Roche |
| selnoflast / NLRP3 inhibitor | Neuroscience, immunology and CVRM | pRED | Phase 1, inflammation, Parkinson’s disease, asthma and coronary artery disease with inflammatory risk | Roche |
| HTT miRNA gene therapy | Neuroscience | pRED | Phase 1, Huntington’s disease | Spark Therapeutics |
| HTT SNP ASO | Neuroscience | pRED | Phase 1, Huntington’s disease | Ionis |
| APOE ASO | Neuroscience | pRED | Phase 1, Alzheimer’s disease | Roche |
| RG6434 NME | Neuroscience | pRED | Phase 1, neurodegenerative disorders | Roche |
| CD19 x CD3 | Immunology | pRED | Phase 1, systemic lupus erythematosus | Roche |
| IBD NME / RG6498 | Immunology | pRED | Phase 1, inflammatory bowel disease | Roche |
| anti-TSLP/IL33 / IL33:TSLP | Immunology and respiratory disease | pRED | Phase 1, COPD and asthma | Qyuns Therapeutics |
| VEGF-IL6 DutaFab | Ophthalmology | pRED | Phase 1, diabetic macular oedema | Roche |
| Ophthalmology NME / RG6327 | Ophthalmology | pRED | Phase 1, geographic atrophy | Roche |
| Ophthalmology NME / RG6913 | Ophthalmology | pRED | Phase 1, diabetic macular oedema | Roche |
| NME / RG6858 | Ophthalmology | pRED | Phase 1, retinal diseases | Roche |
| zosurabalpin / Abx MCP | Infectious diseases and acute care | pRED | Phase 1, Acinetobacter baumannii infections | Roche |
| Coronary artery disease NME / RG6622 | CVRM | pRED | Phase 1, coronary artery disease | Roche |
Genentech research and early development, gRED
| Product or asset | Area | Development layer | Status or focus | Partner |
|---|---|---|---|---|
| cevostamab | Oncology and haematology | gRED | Phase 1, relapsed or refractory multiple myeloma | Genentech |
| autogene cevumeran / iNeST | Oncology and haematology | gRED | Phase 2, personalised cancer vaccine | BioNTech |
| CDK4/2 inhibitor / RGT-419B | Oncology and haematology | gRED | Phase 1, HR-positive/HER2-negative breast cancer | Genentech |
| CDK4 inhibitor | Oncology and haematology | gRED | Phase 1, HR-positive/HER2-negative breast cancer | Genentech |
| enzelkitug / anti-CCR8 | Oncology and haematology | gRED | Phase 1, solid tumours | Genentech |
| AR degrader | Oncology and haematology | gRED | Phase 1, metastatic castration-resistant prostate cancer | Jemincare |
| KRAS G12D inhibitor | Oncology and haematology | gRED | Phase 1, solid tumours | Genentech |
| cMET ADC | Oncology and haematology | gRED | Phase 1, solid tumours | Medilink |
| B7H3-ADC | Oncology and haematology | gRED | Phase 1, solid tumours | Medilink |
| DLL3 ADC | Oncology and haematology | gRED | Phase 1, small-cell lung cancer | Innovent |
| CDH17 ADC | Oncology and haematology | gRED | Phase 1, colorectal cancer | Hansoh Pharma |
| P-BCMA-ALLO1 | Oncology and haematology | gRED | Phase 1, relapsed or refractory multiple myeloma | Poseida Therapeutics |
| P-CD19 x CD20-ALLO1 | Oncology, haematology, neurology and immunology | gRED | Phase 1, B-cell malignancies, MS and SLE | Poseida Therapeutics |
| CHU MINT91 | Oncology and haematology | Chugai / early development | Phase 1, solid tumours | Chugai |
| anti-CTLA-4 Switch antibody / ROSE12 | Oncology and haematology | Chugai / early development | Phase 1, solid tumours | Chugai |
| pan-KRAS inhibitor / AUBE00 | Oncology and haematology | Chugai / early development | Phase 1, solid tumours | Chugai |
| codrituzumab | Oncology and haematology | Chugai / early development | Phase 1, hepatocellular carcinoma | Chugai |
| clesitamig / DLL3 trispecific | Oncology and haematology | Chugai / early development | Phase 1, solid tumours | Chugai |
| TMEM16A potentiator | Immunology and respiratory disease | gRED | Phase 1, muco-obstructive respiratory disease | Genentech |
| Tie2 agonist | Ophthalmology | gRED | Phase 2, diabetic macular oedema | Genentech |
| OpRegen | Ophthalmology | gRED | Phase 2, geographic atrophy | Lineage Cell Therapeutics |
| anti-ILP5 programme | Ophthalmology | gRED | Early retinal disease programme | Genentech |
Partner network
| Partner | Main area |
|---|---|
| Chugai | Oncology, immunology, haematology, neuroscience and ophthalmology |
| Genentech | Early research and development, especially oncology and advanced modalities |
| Biogen Idec | Immunology, haematology and neuroscience |
| BioNTech | Individualised cancer vaccines |
| Alnylam Pharmaceuticals | Hypertension |
| Ionis | IgA nephropathy and Huntington’s disease |
| Carmot Therapeutics | Obesity, diabetes and metabolic disease |
| Telavant | TL1A immunology programmes |
| Sarepta | Duchenne muscular dystrophy gene therapy |
| Spark Therapeutics | Gene therapy and Huntington’s disease |
| Poseida Therapeutics | Allogeneic CAR-T therapies |
| Medilink | Oncology ADCs |
| Seagen | Polivy |
| Halozyme | Subcutaneous formulations |
| Shionogi | Xofluza |
| Pfizer | Immunology bispecific programme |
| 89bio | MASH |
| Zealand | Obesity and metabolic disease |
| Lineage Cell Therapeutics | Retinal cell therapy |
| Prothena | Parkinson’s disease |
| ForSight VISION4 | Susvimo port delivery system |
| ImmunoGen | Kadcyla |
| Jazz Pharma | Tecentriq combination |
| Amgen | Astegolimab |
| PTC Therapeutics | Evrysdi |
| SMA Foundation | Evrysdi |
| Qyuns Therapeutics | IL-33 / TSLP immunology programme |
| Innovent | DLL3 ADC |
| Hansoh Pharma | CDH17 ADC |
| Jemincare | AR degrader |
Where people fit inside the company
| Person or team | Where they likely fit |
|---|---|
| Discovery scientist | pRED, gRED, Chugai or a specialised partner programme |
| Translational scientist | pRED, gRED or Global Product Development |
| Clinical development scientist | Global Product Development |
| Regulatory scientist | Global development, diagnostics launch teams or regional regulatory teams |
| Diagnostics assay scientist | Core lab, molecular lab, pathology lab, sequencing or near-patient care |
| Digital product analyst | navify, lab insights, healthcare insights or diagnostics digital solutions |
| Laboratory workflow specialist | Core lab, pathology lab, molecular lab or point-of-care diagnostics |
| Bioinformatics or sequencing scientist | Sequencing, KAPA, AVENIO, AXELIOS or molecular diagnostics |
| Medical affairs specialist | Pharma therapeutic areas or diagnostics medical functions |
| Business development analyst | Corporate Business Development or partner-facing pipeline teams |
| Governance or legal specialist | Board support, General Counsel, compliance, sustainability or corporate functions |
Acquired companies and product lines still visible in Roche
Roche’s current structure includes several products, platforms and development programmes that came through acquisition or strategic group integration. This is not a full acquisition history. It lists acquired companies or acquired assets that are still visible in Roche’s current products, diagnostics architecture or development pipeline.
| Company or asset | Year | How it appears in Roche today | Related current products, platforms or programmes |
|---|---|---|---|
| Boehringer Mannheim / Corange Group | 1998 | Foundation of the modern Roche Diagnostics scale-up | Roche Diagnostics, core lab, cobas systems, diabetes care and diagnostics infrastructure |
| Chugai Pharmaceutical | 2002 | Japanese affiliate and innovation partner within the Roche Group | Alecensa, Hemlibra, Enspryng, PiaSky, Chugai-originated antibody engineering and oncology assets |
| Ventana Medical Systems | 2008 | Roche Tissue Diagnostics | VENTANA®, BenchMark ULTRA PLUS, DP600, pathology assays and tissue diagnostics |
| Genentech | 2009 | Roche’s US biotechnology and early research organisation | gRED, oncology, immunology, neuroscience, bispecifics, KRAS, CAR-T and cancer vaccine programmes |
| Ariosa Diagnostics | 2015 | Non-invasive prenatal testing | Harmony® prenatal test and Ariosa cell-free DNA system |
| Kapa Biosystems | 2015 | NGS and PCR reagent capability | KAPA workflows, library preparation and sequencing-related reagents |
| mySugr | 2017 | Digital diabetes management | mySugr, Accu-Chek digital services, diabetes care platform |
| Viewics | 2017 | Laboratory analytics capability | Lab analytics, operational insights and digital laboratory tooling |
| Foundation Medicine | 2018 | Cancer genomic profiling and oncology data infrastructure | Foundation Medicine CGP tests, oncology profiling and precision oncology infrastructure |
| Flatiron Health | 2018 | Oncology real-world data and clinical data infrastructure | Oncology EHR software, real-world evidence and cancer research data |
| Spark Therapeutics | 2019 | Gene therapy capability | Gene therapy programmes, including haemophilia and inherited disease assets |
| GenMark Diagnostics | 2021 | Syndromic molecular diagnostics | ePlex panels, including gastrointestinal and infectious disease testing |
| TIB Molbiol | 2021 | Flexible PCR assay development | TIB Molbiol assays, LightCycler® and MagNA Pure workflows |
| Telavant | 2023 | TL1A immunology programme rights | afimkibart / RVT-3101, inflammatory bowel disease and related immunology programmes |
| Carmot Therapeutics | 2024 | Metabolic disease pipeline | CT-388 / enicepatide, CT-996 and CT-868 for obesity and diabetes |
| Poseida Therapeutics | 2025 | Allogeneic CAR-T and genetic medicine platform | P-BCMA-ALLO1, P-CD19 x CD20-ALLO1, oncology, immunology and neuroscience CAR-T programmes |
| 89bio | 2025 | MASH and cardiometabolic pipeline | pegozafermin, MASH with fibrosis and CVRM expansion |
This acquisition layer helps explain Roche’s structure. Some visible product families came from earlier diagnostics consolidation, including Boehringer Mannheim, Ventana, Ariosa, Kapa, TIB Molbiol and GenMark. Others expanded Roche’s pharma research and pipeline architecture, including Genentech, Chugai, Spark, Telavant, Carmot, Poseida and 89bio. Data-oriented acquisitions such as Foundation Medicine, Flatiron Health, mySugr and Viewics strengthened Roche’s digital and evidence infrastructure.
Roche’s own materials describe Boehringer Mannheim as strengthening Roche’s diagnostics position, Chugai as a Roche Group member from 2002, Genentech as becoming part of Roche in 2009, Ventana as the basis of Roche Tissue Diagnostics, Kapa as strengthening NGS offerings, TIB Molbiol as expanding PCR and molecular diagnostics, GenMark as adding multi-pathogen molecular testing, Carmot as adding obesity and diabetes assets, Poseida as adding allogeneic CAR-T and genetic medicine capabilities, and 89bio as adding pegozafermin for MASH.
What matters strategically
Roche combines medicines, diagnostic systems, research engines, laboratory infrastructure, digital tools and partner networks. Pharma creates therapeutic assets. Diagnostics creates clinical testing infrastructure and data flow. pRED and gRED feed early science into later-stage development. Global Product Development turns selected assets into regulated products. Marketed product programmes extend approved medicines into new clinical settings.
The technical direction is platform-based. In pharma, the visible themes include bispecific antibodies, antibody-drug conjugates, KRAS and PI3K targeting, CAR-T, personalised cancer vaccines, Brainshuttle neuroscience assets, RNA and ASO approaches, gene therapy, GLP-1/GIP metabolic assets and MASH programmes. In diagnostics, the visible themes include sequencing, molecular testing, digital pathology, blood-based biomarkers, near-patient testing, laboratory analytics and AI-enabled diagnostic algorithms.
For a CEO, Roche shows how a large healthcare company manages continuity, lifecycle value and renewal. For a CTO, it shows how platforms, instruments, assays, data systems and therapeutics can sit inside one regulated architecture. For a scientist or analyst, it shows where work enters the system: discovery, early development, global development, diagnostics, marketed-product expansion, regulatory execution or external partnership.
Limits of this report
This report is based on Roche governance, product and pipeline information reviewed from supplied notes and Roche public webpages in May 2026. Pipeline information changes as programmes progress, pause, fail, file or receive approval. Product descriptions are simplified for orientation and do not replace regulatory labels, prescribing information or Roche’s official product pages.
Abbreviations
| Abbreviation | Meaning |
|---|---|
| ADC | Antibody-drug conjugate |
| AI | Additional indication |
| ASO | Antisense oligonucleotide |
| CE | European conformity |
| CAR-T | Chimeric antigen receptor T-cell therapy |
| CNV | Choroidal neovascularisation |
| CVRM | Cardiovascular, renal and metabolism |
| DLBCL | Diffuse large B-cell lymphoma |
| DME | Diabetic macular oedema |
| EUA | Emergency use authorisation |
| gRED | Genentech Research and Early Development |
| HCC | Hepatocellular carcinoma |
| IBD | Inflammatory bowel disease |
| IHC | Immunohistochemistry |
| ISH | In situ hybridisation |
| IVD | In vitro diagnostic |
| MASH | Metabolic dysfunction-associated steatohepatitis |
| NGS | Next-generation sequencing |
| NME | New molecular entity |
| NSCLC | Non-small cell lung cancer |
| OUS | Outside the US |
| pRED | Roche Pharma Research and Early Development |
| PNH | Paroxysmal nocturnal haemoglobinuria |
| RUO | Research use only |
| SMA | Spinal muscular atrophy |
| SLE | Systemic lupus erythematosus |
| US | FDA approval or US market |
| WW | Worldwide |
Links
Roche pipeline:
https://www.roche.com/solutions/pipeline
Roche governance:
https://www.roche.com/about/governance
Former Board member CV archive:
https://www.roche.com/about/governance/archiv-former-cvs.
